Global and China Postmenopausal Vaginal Atrophy Drugs Market Insights, Forecast to 2026

Publisher Name :
Date: 15-Oct-2020
No. of pages: 129
Inquire Before Buying

Postmenopausal Vaginal Atrophy Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Postmenopausal Vaginal Atrophy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Postmenopausal Vaginal Atrophy Drugs market is segmented into

Premarin

Vagifem

Estrace

Estring

Femring

Segment by Application, the Postmenopausal Vaginal Atrophy Drugs market is segmented into

Vaginal Gels

Creams

Tablets

Rings

Patches

Regional and Country-level Analysis

The Postmenopausal Vaginal Atrophy Drugs market is analysed and market size information is provided by regions (countries).

The key regions covered in the Postmenopausal Vaginal Atrophy Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Postmenopausal Vaginal Atrophy Drugs Market Share Analysis

Postmenopausal Vaginal Atrophy Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Postmenopausal Vaginal Atrophy Drugs business, the date to enter into the Postmenopausal Vaginal Atrophy Drugs market, Postmenopausal Vaginal Atrophy Drugs product introduction, recent developments, etc.

The major vendors covered:

Actavis plc

Bionovo, Inc.

Endoceutics, Inc.

Novo Nordisk A/S

Pfizer Inc.

Teva Pharmaceuticals Ltd.

Therapeutics MD, Inc.

Shionogi & Company

Allergan plc

Shionogi & Co. Ltd.

Global and China Postmenopausal Vaginal Atrophy Drugs Market Insights, Forecast to 2026

Table of Contents
1 Study Coverage
1.1 Postmenopausal Vaginal Atrophy Drugs Product Introduction
1.2 Market Segments
1.3 Key Postmenopausal Vaginal Atrophy Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type
1.4.2 Premarin
1.4.3 Vagifem
1.4.4 Estrace
1.4.5 Estring
1.4.6 Femring
1.5 Market by Application
1.5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application
1.5.2 Vaginal Gels
1.5.3 Creams
1.5.4 Tablets
1.5.5 Rings
1.5.6 Patches
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size, Estimates and Forecasts
2.1.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue 2015-2026
2.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales 2015-2026
2.2 Global Postmenopausal Vaginal Atrophy Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.3 Postmenopausal Vaginal Atrophy Drugs Historical Market Size by Region (2015-2020)
2.3.1 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.3.2 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
2.4 Postmenopausal Vaginal Atrophy Drugs Market Estimates and Projections by Region (2021-2026)
2.4.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Region (2021-2026)
2.4.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Region (2021-2026)
3 Global Postmenopausal Vaginal Atrophy Drugs Competitor Landscape by Players
3.1 Global Top Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers
3.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (2015-2020)
3.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Global Postmenopausal Vaginal Atrophy Drugs Manufacturers by Revenue
3.2.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Postmenopausal Vaginal Atrophy Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Postmenopausal Vaginal Atrophy Drugs Revenue in 2019
3.2.5 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Manufacturers
3.4 Global Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution, Product Types
3.4.1 Postmenopausal Vaginal Atrophy Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Type (2015-2020)
4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020)
4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2015-2020)
4.1.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Application (2015-2020)
5.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020)
5.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2015-2020)
5.1.3 Postmenopausal Vaginal Atrophy Drugs Price by Application (2015-2020)
5.2 Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Price Forecast by Application (2021-2026)
6 China by Players, Type and Application
6.1 China Postmenopausal Vaginal Atrophy Drugs Market Size YoY Growth 2015-2026
6.1.1 China Postmenopausal Vaginal Atrophy Drugs Sales YoY Growth 2015-2026
6.1.2 China Postmenopausal Vaginal Atrophy Drugs Revenue YoY Growth 2015-2026
6.1.3 China Postmenopausal Vaginal Atrophy Drugs Market Share in Global Market 2015-2026
6.2 China Postmenopausal Vaginal Atrophy Drugs Market Size by Players (International and Local Players)
6.2.1 China Top Postmenopausal Vaginal Atrophy Drugs Players by Sales (2015-2020)
6.2.2 China Top Postmenopausal Vaginal Atrophy Drugs Players by Revenue (2015-2020)
6.3 China Postmenopausal Vaginal Atrophy Drugs Historic Market Review by Type (2015-2020)
6.3.1 China Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
6.3.2 China Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2015-2020)
6.3.3 China Postmenopausal Vaginal Atrophy Drugs Price by Type (2015-2020)
6.4 China Postmenopausal Vaginal Atrophy Drugs Market Estimates and Forecasts by Type (2021-2026)
6.4.1 China Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type (2021-2026)
6.4.2 China Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Type (2021-2026)
6.4.3 China Postmenopausal Vaginal Atrophy Drugs Price Forecast by Type (2021-2026)
6.5 China Postmenopausal Vaginal Atrophy Drugs Historic Market Review by Application (2015-2020)
6.5.1 China Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
6.5.2 China Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2015-2020)
6.5.3 China Postmenopausal Vaginal Atrophy Drugs Price by Application (2015-2020)
6.6 China Postmenopausal Vaginal Atrophy Drugs Market Estimates and Forecasts by Application (2021-2026)
6.6.1 China Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application (2021-2026)
6.6.2 China Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Application (2021-2026)
6.6.3 China Postmenopausal Vaginal Atrophy Drugs Price Forecast by Application (2021-2026)
7 North America
7.1 North America Postmenopausal Vaginal Atrophy Drugs Market Size YoY Growth 2015-2026
7.2 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
7.2.1 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2015-2020)
7.2.2 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2015-2020)
7.2.3 U.S.
7.2.4 Canada
8 Europe
8.1 Europe Postmenopausal Vaginal Atrophy Drugs Market Size YoY Growth 2015-2026
8.2 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
8.2.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country
8.2.2 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country
8.2.3 Germany
8.2.4 France
8.2.5 U.K.
8.2.6 Italy
8.2.7 Russia
9 Asia Pacific
9.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Size YoY Growth 2015-2026
9.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
9.2.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2015-2020)
9.2.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region
9.2.3 China
9.2.4 Japan
9.2.5 South Korea
9.2.6 India
9.2.7 Australia
9.2.8 Taiwan
9.2.9 Indonesia
9.2.10 Thailand
9.2.11 Malaysia
9.2.12 Philippines
9.2.13 Vietnam
10 Latin America
10.1 Latin America Postmenopausal Vaginal Atrophy Drugs Market Size YoY Growth 2015-2026
10.2 Latin America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
10.2.1 Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country
10.2.2 Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size YoY Growth 2015-2026
11.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
11.2.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country
11.2.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 Actavis plc
12.1.1 Actavis plc Corporation Information
12.1.2 Actavis plc Description and Business Overview
12.1.3 Actavis plc Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
12.1.5 Actavis plc Recent Development
12.2 Bionovo, Inc.
12.2.1 Bionovo, Inc. Corporation Information
12.2.2 Bionovo, Inc. Description and Business Overview
12.2.3 Bionovo, Inc. Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.2.5 Bionovo, Inc. Recent Development
12.3 Endoceutics, Inc.
12.3.1 Endoceutics, Inc. Corporation Information
12.3.2 Endoceutics, Inc. Description and Business Overview
12.3.3 Endoceutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.3.5 Endoceutics, Inc. Recent Development
12.4 Novo Nordisk A/S
12.4.1 Novo Nordisk A/S Corporation Information
12.4.2 Novo Nordisk A/S Description and Business Overview
12.4.3 Novo Nordisk A/S Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Products Offered
12.4.5 Novo Nordisk A/S Recent Development
12.5 Pfizer Inc.
12.5.1 Pfizer Inc. Corporation Information
12.5.2 Pfizer Inc. Description and Business Overview
12.5.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.5.5 Pfizer Inc. Recent Development
12.6 Teva Pharmaceuticals Ltd.
12.6.1 Teva Pharmaceuticals Ltd. Corporation Information
12.6.2 Teva Pharmaceuticals Ltd. Description and Business Overview
12.6.3 Teva Pharmaceuticals Ltd. Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.6.5 Teva Pharmaceuticals Ltd. Recent Development
12.7 Therapeutics MD, Inc.
12.7.1 Therapeutics MD, Inc. Corporation Information
12.7.2 Therapeutics MD, Inc. Description and Business Overview
12.7.3 Therapeutics MD, Inc. Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.7.5 Therapeutics MD, Inc. Recent Development
12.8 Shionogi & Company
12.8.1 Shionogi & Company Corporation Information
12.8.2 Shionogi & Company Description and Business Overview
12.8.3 Shionogi & Company Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Products Offered
12.8.5 Shionogi & Company Recent Development
12.9 Allergan plc
12.9.1 Allergan plc Corporation Information
12.9.2 Allergan plc Description and Business Overview
12.9.3 Allergan plc Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Allergan plc Postmenopausal Vaginal Atrophy Drugs Products Offered
12.9.5 Allergan plc Recent Development
12.10 Shionogi & Co. Ltd.
12.10.1 Shionogi & Co. Ltd. Corporation Information
12.10.2 Shionogi & Co. Ltd. Description and Business Overview
12.10.3 Shionogi & Co. Ltd. Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.10.5 Shionogi & Co. Ltd. Recent Development
12.11 Actavis plc
12.11.1 Actavis plc Corporation Information
12.11.2 Actavis plc Description and Business Overview
12.11.3 Actavis plc Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
12.11.5 Actavis plc Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Postmenopausal Vaginal Atrophy Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Postmenopausal Vaginal Atrophy Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
Table 1. Postmenopausal Vaginal Atrophy Drugs Market Segments
Table 2. Ranking of Global Top Postmenopausal Vaginal Atrophy Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Premarin
Table 5. Major Manufacturers of Vagifem
Table 6. Major Manufacturers of Estrace
Table 7. Major Manufacturers of Estring
Table 8. Major Manufacturers of Femring
Table 9. Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 10. Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 11. Global Postmenopausal Vaginal Atrophy Drugs Sales by Regions 2015-2020 (K Units)
Table 12. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Regions (2015-2020)
Table 13. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 15. Global Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 16. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturers (2015-2020)
Table 17. Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global Postmenopausal Vaginal Atrophy Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2019)
Table 19. Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Price (2015-2020) (USD/Unit)
Table 22. Postmenopausal Vaginal Atrophy Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
Table 24. Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 27. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2015-2020)
Table 28. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2015-2020) (US$ Million)
Table 29. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2015-2020)
Table 30. Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 31. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2021-2026)
Table 32. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 33. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2015-2020)
Table 34. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2021-2026)
Table 35. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Application (2021-2026)
Table 36. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2015-2020) (US$ Million)
Table 37. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share Forecast by Application (2021-2026)
Table 38. China Postmenopausal Vaginal Atrophy Drugs Sales (K Units) of Key Companies (2015-2020)
Table 39. China Postmenopausal Vaginal Atrophy Drugs Sales Share by Company (2015-2020)
Table 40. China Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Company (2015-2020)
Table 41. China Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2015-2020)
Table 42. China Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2015-2020)
Table 43. China Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) Market Share by Type (2015-2020)
Table 44. China Postmenopausal Vaginal Atrophy Drugs Price (K Units) by Type (2015-2020)
Table 45. China Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2021-2026)
Table 46. China Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2021-2026)
Table 47. China Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) Market Share by Type (2021-2026)
Table 48. China Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2021-2026)
Table 49. China Postmenopausal Vaginal Atrophy Drugs Price (K Units) by Type (2021-2026)
Table 50. China Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2015-2020)
Table 51. China Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2015-2020)
Table 52. China Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) Market Share by Application (2015-2020)
Table 53. China Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2021-2026)
Table 54. China Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2021-2026)
Table 55. China Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) Market Share by Application (2021-2026)
Table 56. China Postmenopausal Vaginal Atrophy Drugs Revenue Share by Application (2021-2026)
Table 57. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2015-2020) (K Units)
Table 58. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2015-2020)
Table 59. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 60. North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2015-2020)
Table 61. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2015-2020) (K Units)
Table 62. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2015-2020)
Table 63. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 64. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2015-2020)
Table 65. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2015-2020) (K Units)
Table 66. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2015-2020)
Table 67. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2015-2020) (US$ Million)
Table 68. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2015-2020)
Table 69. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2015-2020) (K Units)
Table 70. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2015-2020)
Table 71. Latin Americaa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 72. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2015-2020)
Table 73. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2015-2020) (K Units)
Table 74. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2015-2020)
Table 75. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 76. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2015-2020)
Table 77. Actavis plc Corporation Information
Table 78. Actavis plc Description and Business Overview
Table 79. Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 80. Actavis plc Postmenopausal Vaginal Atrophy Drugs Product
Table 81. Actavis plc Recent Development
Table 82. Bionovo, Inc. Corporation Information
Table 83. Bionovo, Inc. Description and Business Overview
Table 84. Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 85. Bionovo, Inc. Product
Table 86. Bionovo, Inc. Recent Development
Table 87. Endoceutics, Inc. Corporation Information
Table 88. Endoceutics, Inc. Description and Business Overview
Table 89. Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 90. Endoceutics, Inc. Product
Table 91. Endoceutics, Inc. Recent Development
Table 92. Novo Nordisk A/S Corporation Information
Table 93. Novo Nordisk A/S Description and Business Overview
Table 94. Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 95. Novo Nordisk A/S Product
Table 96. Novo Nordisk A/S Recent Development
Table 97. Pfizer Inc. Corporation Information
Table 98. Pfizer Inc. Description and Business Overview
Table 99. Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 100. Pfizer Inc. Product
Table 101. Pfizer Inc. Recent Development
Table 102. Teva Pharmaceuticals Ltd. Corporation Information
Table 103. Teva Pharmaceuticals Ltd. Description and Business Overview
Table 104. Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 105. Teva Pharmaceuticals Ltd. Product
Table 106. Teva Pharmaceuticals Ltd. Recent Development
Table 107. Therapeutics MD, Inc. Corporation Information
Table 108. Therapeutics MD, Inc. Description and Business Overview
Table 109. Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 110. Therapeutics MD, Inc. Product
Table 111. Therapeutics MD, Inc. Recent Development
Table 112. Shionogi & Company Corporation Information
Table 113. Shionogi & Company Description and Business Overview
Table 114. Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 115. Shionogi & Company Product
Table 116. Shionogi & Company Recent Development
Table 117. Allergan plc Corporation Information
Table 118. Allergan plc Description and Business Overview
Table 119. Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 120. Allergan plc Product
Table 121. Allergan plc Recent Development
Table 122. Shionogi & Co. Ltd. Corporation Information
Table 123. Shionogi & Co. Ltd. Description and Business Overview
Table 124. Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 125. Shionogi & Co. Ltd. Product
Table 126. Shionogi & Co. Ltd. Recent Development
Table 127. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 128. Key Challenges
Table 129. Market Risks
Table 130. Main Points Interviewed from Key Postmenopausal Vaginal Atrophy Drugs Players
Table 131. Postmenopausal Vaginal Atrophy Drugs Customers List
Table 132. Postmenopausal Vaginal Atrophy Drugs Distributors List
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Postmenopausal Vaginal Atrophy Drugs Product Picture
Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Premarin Product Picture
Figure 4. Vagifem Product Picture
Figure 5. Estrace Product Picture
Figure 6. Estring Product Picture
Figure 7. Femring Product Picture
Figure 8. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application in 2020 & 2026
Figure 9. Vaginal Gels
Figure 10. Creams
Figure 11. Tablets
Figure 12. Rings
Figure 13. Patches
Figure 14. Postmenopausal Vaginal Atrophy Drugs Report Years Considered
Figure 15. Global Postmenopausal Vaginal Atrophy Drugs Market Size 2015-2026 (US$ Million)
Figure 16. Global Postmenopausal Vaginal Atrophy Drugs Sales 2015-2026 (K Units)
Figure 17. Global Postmenopausal Vaginal Atrophy Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 18. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2015-2020)
Figure 19. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region in 2019
Figure 20. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2015-2020)
Figure 21. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region in 2019
Figure 22. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturer in 2019
Figure 23. The Top 10 and 5 Players Market Share by Postmenopausal Vaginal Atrophy Drugs Revenue in 2019
Figure 24. Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 25. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Figure 26. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2019
Figure 27. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2015-2020)
Figure 28. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type in 2019
Figure 29. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Price Range (2015-2020)
Figure 30. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Figure 31. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application in 2019
Figure 32. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2015-2020)
Figure 33. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application in 2019
Figure 34. China Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2015-2026 (K Units)
Figure 35. China Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2015-2026 (US$ Million)
Figure 36. China Postmenopausal Vaginal Atrophy Drugs Market Share in Global Market 2015-2026
Figure 37. China 5 and 10 Largest Postmenopausal Vaginal Atrophy Drugs Players Market Share by Revenue in Postmenopausal Vaginal Atrophy Drugs in 2019
Figure 38. China Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2015-2020)
Figure 39. China Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate by Type in 2015 & 2019
Figure 40. China Postmenopausal Vaginal Atrophy Drugs Revenue Share by Application (2015-2020)
Figure 41. China Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate by Application in 2015 & 2019
Figure 42. North America Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 43. North America Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country in 2019
Figure 45. North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country in 2019
Figure 46. U.S. Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 47. U.S. Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. Canada Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 49. Canada Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Europe Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 51. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 52. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country in 2019
Figure 53. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country in 2019
Figure 54. Germany Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 55. Germany Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. France Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 57. France Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. U.K. Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 59. U.K. Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Italy Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 61. Italy Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Russia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 63. Russia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 65. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 66. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region in 2019
Figure 67. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region in 2019
Figure 68. China Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 69. China Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Japan Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 71. Japan Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. South Korea Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 73. South Korea Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. India Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 75. India Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Australia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 77. Australia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Taiwan Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 79. Taiwan Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Indonesia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 81. Indonesia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Thailand Postmenopausal Vaginal Atrophy Drugs Sales Grow
  • Global Medical Foods for Inborn Errors of Metabolism Market Growth 2020-2025
    Published: 30-Oct-2020        Price: US 3660 Onwards        Pages: 135
    According to this study, over the next five years the Medical Foods for Inborn Errors of Metabolism market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Medical Foods for Inborn Errors of Metabolism business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growt......
  • Global OX40 Receptor Agonist Market Growth 2020-2025
    Published: 30-Oct-2020        Price: US 3660 Onwards        Pages: 160
    According to this study, over the next five years the OX40 Receptor Agonist market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in OX40 Receptor Agonist business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of OX40 Receptor Agonist market ......
  • Global NF-KB Inhibitors Market Growth 2020-2025
    Published: 30-Oct-2020        Price: US 3660 Onwards        Pages: 135
    According to this study, over the next five years the NF-KB Inhibitors market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in NF-KB Inhibitors business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of NF-KB Inhibitors market by product type......
  • Global and United States Diabetes Treatment Drugs Market Growth (Status and Outlook) 2020-2025
    Published: 30-Oct-2020        Price: US 3960 Onwards        Pages: 103
    This study researches the Diabetes Treatment Drugs market overview in global and United States market. For the global market, this report focuses on the market size of Diabetes Treatment Drugs in global, regional and country-level market, by regions (countries), by Type, and by Application, for the period 2015-2025. It also includes the Diabetes Treatment Drugs provides details and data information by players for the period 2015-2020. For United States market, the r......
  • Global Diabetes Treatment Drugs Market Growth (Status and Outlook) 2020-2025
    Published: 30-Oct-2020        Price: US 3660 Onwards        Pages: 131
    According to this study, over the next five years the Diabetes Treatment Drugs market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Diabetes Treatment Drugs business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Diabetes Treatment Drugs market by ......
  • Global Knee Hyaluronic Acid Injection Market Growth 2020-2025
    Published: 30-Oct-2020        Price: US 3660 Onwards        Pages: 136
    According to this study, over the next five years the Knee Hyaluronic Acid Injection market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Knee Hyaluronic Acid Injection business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Knee Hyalur......
  • Global Medical Nitroglycerin Spray Market Growth 2020-2025
    Published: 30-Oct-2020        Price: US 3660 Onwards        Pages: 135
    According to this study, over the next five years the Medical Nitroglycerin Spray market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Medical Nitroglycerin Spray business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Medical Nitroglyc......
  • Global Ertapenem API Market Growth 2020-2025
    Published: 30-Oct-2020        Price: US 3660 Onwards        Pages: 135
    According to this study, over the next five years the Ertapenem API market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Ertapenem API business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Ertapenem API market by product type, applica......
  • Global and Blockchain in Pharma Supply Chain Market Growth (Status and Outlook) 2020-2025
    Published: 30-Oct-2020        Price: US 3960 Onwards        Pages: 101
    This study researches the Blockchain in Pharma Supply Chain market overview in global and market. For the global market, this report focuses on the market size of Blockchain in Pharma Supply Chain in global, regional and country-level market, by regions (countries), by Type, and by Application, for the period 2015-2025. It also includes the Blockchain in Pharma Supply Chain provides details and data information by players for the period 2015-2020. For market, the re......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs